Trial reportScientific reports2022
Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial.
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- Home-based low-level light therapy using a commercial LED mask for dry eye disease.International ophthalmology · 2026Observational
- Near-Infrared and Red-Light Photobiomodulation for Ocular Aging and Diseases: A Narrative Review.Ophthalmology and therapy · 2026Review
- Promotive effects of 830-nm Photobiomodulation on corneal epithelial wound healing and rho-gtpase expression in a rat alkali burn model.Lasers in medical science · 2026Article
- Evolving treatments for Sjögren disease: current approaches and emerging targets.Internal medicine journal · 2026Review
- Effects of Lotilaner Ophthalmic Solution, 0.25% onClinical ophthalmology (Auckland, N.Z.) · 2026Article
- Current and Emerging Approaches in the Management of Severe Ocular Surface Disease.Medicina (Kaunas, Lithuania) · 2025Review
- Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery: A Prospective Double-Masked Randomized Controlled Clinical Trial.Ophthalmology and therapy · 2025Article
- Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis.Ophthalmology and therapy · 2025Article
- Effect of Heating and Massaging of Meibomian Glands on Their Imaging.Medicina (Kaunas, Lithuania) · 2024Article
- Efficacy and Safety of Quantum Molecular Resonance Electrotherapy in Patients with Aqueous-Deficient, Evaporative and Mixed-Type Dry Eye: A Randomized Interventional Study.Ophthalmology and therapy · 2024Article
- Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- The Anti-Inflammatory Effect of Multi-Wavelength Light-Emitting Diode Irradiation Attenuates Dry Eye Symptoms in a Scopolamine-Induced Mouse Model of Dry Eye.International journal of molecular sciences · 2023Article
- Recent advances in age-related meibomian gland dysfunction (ARMGD).The ocular surface · 2023Review
- Article
- Intense pulsed-light treatment improves objective optical quality in patients with meibomian gland dysfunction.BMC ophthalmology · 2023Article
- Serial Sessions of a Novel Low-Level Light Therapy Device for Home Treatment of Dry Eye Disease.Ophthalmology and therapy · 2023Article
- Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy.Clinical optometry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the efficacy of low-level light therapy (LLLT) with near-infrared light-emitting diodes (LED-LLLT) for the treatment of dry eye. 40 patients were randomly assigned with a 1:1 allocation ratio to receive LED-LLLT (LLLT group, n = 20) or placebo treatment (placebo group, n = 20). Patients in the LLLT group received LLLT twice a week for 3 weeks, for a total of 6 treatment sessions. The primary endpoint was the changes in the fluorescein corneal staining (FCS) score. The secondary endpoints were the changes in the ocular surface disease index (OSDI) score, lissamine green conjunctival staining (LGCS) scores, tear film break-up time (TBUT), Schirmer test, and the meibomian gland dysfunction (MGD) index. These were evaluated before treatment and 4 weeks after start of treatment. The mean difference of score change in primary endpoint revealed significant improvement in the LLLT group, compared to the placebo. Among secondary endpoints, LGCS, Schirmer's test, upper meibography scores showed significant improvements, while TBUT, lid debris, lid swelling, lid telangiectasia, meibomian gland secretion and expressibility scores had slight improvement without significant differences. No serious adverse events were observed. The use of LED-LLLT for the treatment of dry eye and MGD appears to be safe and beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.